Cellular and Molecular Life Sciences

, Volume 74, Issue 23, pp 4293–4303 | Cite as

Periostin in inflammation and allergy

  • Kenji Izuhara
  • Satoshi Nunomura
  • Yasuhiro Nanri
  • Masahiro Ogawa
  • Junya Ono
  • Yasutaka Mitamura
  • Tomohito Yoshihara
Multi-author review

Abstract

We found for the first time that IL-4 and IL-13, signature type 2 cytokines, are able to induce periostin expression. We and others have subsequently shown that periostin is highly expressed in chronic inflammatory diseases―asthma, atopic dermatitis, eosinophilc chronic sinusitis/chronic rhinosinusitis with nasal polyp, and allergic conjunctivitis—and that periostin plays important roles in the pathogenesis of these diseases. The epithelial/mesenchymal interaction via periostin is important for the onset of allergic inflammation, in which periostin derived from fibroblasts acts on epithelial cells or fibroblasts, activating their NF-κB. Moreover, the immune cell/non-immune cell interaction via periostin may be also involved. Now the significance of periostin has been expanded into other inflammatory or fibrotic diseases such as scleroderma and pulmonary fibrosis. The cross-talk of periostin with TGF-β or pro-inflammatory cytokines is important for the underlying mechanism of these diseases. Because of its pathogenic importance and broad expression, diagnostics or therapeutic drugs can be potentially developed to target periostin as a means of treating these diseases.

Keywords

Periostin Matricellular protein Allergy Biomarker Asthma Atopic dermatitis Allergic conjunctivitis Scleroderma Pulmonary fibrosis Epithelial/mesenchymal interaction Cross-talk IL-4 IL-13 TGF-β 

Notes

Acknowledgements

We thank Dr. Dovie R. Wylie for the critical review of this manuscript. We also thank the colleagues and collaborators as follows for contributing to the present work: Go Takayama, Masaru Uchida, Miho Masuoka, Hiroshi Shiraishi, Minako Ontsuka, Kazuto Taniguchi, Kazuhiko Arima, Shoichi Suzuki, Shoichiro Ohta, Go Kato, Koichiro Takahashi, Shin-ichiro Hayashi (Saga Medical School), Noriko Yuyama (Genox Research, Inc.), Akihiro Ishida, Nobuo Ohta (Yamagata University), Takahiro Ninomiya, Shigeharu Fujieda (Fukui University), Hiroshi Fujishima (Tsurumi University), Naoko Okada, Kenji Matsumoto (National Research Institute for Child Health and Development Laboratory), Yuzaburo Inoue, Naoki Shimojo (Chiba University), Yoshihiro Kanemitsu, Tadao Nagasaki, Tomoko Tajiri, Hisako Matsumoto (Kyoto University), Masako Matsuzaka, Koichi Fukunaga (Keio University), Koichiro Asano (Tokai University), Yorihisa Kotobuki, Ichiro Katayama (Osaka University), Kenzen Kou, Yukie Yamaguchi, Michiko Aihara (Yokohama City University), Timothy Hinks, Peter Howarth (Southampton University Hospital), Mi-Ae Kim, Hae-Sim Park (Ajou University), Anna James, Sven-Erik Dahlen (Karolinska Institutet), Ayami Kamei, Masayuki Takai, Yoshinori Azuma (Shino-Test Co.), Simon J. Conway (Indiana University), Masaki Okamoto, Tomoaki Hoshino, Kiminori Fujimoto (Kurume University), Naoko Kushima, Hiroshi Ishii, Junichi Kadota (Oita University), Hiroshi Yamamoto, Masayuki Hanaoka (Shinshu University), Noriho Sakamoto, Shigeru Kohno (Nagasaki University), Keiichi Akasaka, Hironori Sagara (Dokkyo Medical University Koshigaya Hospital), and Takeshi Johkoh (Kinki Central Hospital of Mutual Aid Association of Public Teachers).

References

  1. 1.
    Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279–1288. doi: 10.1007/s00018-013-1494-y CrossRefPubMedGoogle Scholar
  2. 2.
    Ontsuka K, Kotobuki Y, Shiraishi H, Serada S, Ohta S, Tanemura A, Yang L, Fujimoto M, Arima K, Suzuki S, Murota H, Toda S, Kudo A, Conway SJ, Narisawa Y, Katayama I, Izuhara K, Naka T (2012) Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. Exp Dermatol 21:331–336. doi: 10.1111/j.1600-0625.2012.01454.x CrossRefPubMedGoogle Scholar
  3. 3.
    Nishiyama T, Kii I, Kashima TG, Kikuchi Y, Ohazama A, Shimazaki M, Fukayama M, Kudo A (2011) Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS One 6:e18410. doi: 10.1371/journal.pone.0018410 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Elliott CG, Wang J, Guo X, Xu SW, Eastwood M, Guan J, Leask A, Conway SJ, Hamilton DW (2012) Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair. J Cell Sci 125:121–132. doi: 10.1242/jcs.087841 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, Yoshida NL, Maeda M, Pandit A, Lordan JL, Kamogawa Y, Arima K, Nagumo F, Sugimachi M, Berger A, Richards I, Roberds SL, Yamashita T, Kishi F, Kato H, Arai K, Ohshima K, Tadano J, Hamasaki N, Miyatake S, Sugita Y, Holgate ST, Izuhara K (2002) Analysis of novel disease-related genes in bronchial asthma. Cytokine 19:287–296CrossRefPubMedGoogle Scholar
  6. 6.
    Izuhara K, Arima K, Yasunaga S (2002) IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies. Curr Drug Targets Inflamm Allergy 1:263–269CrossRefPubMedGoogle Scholar
  7. 7.
    Izuhara K, Arima K, Kanaji S, Ohta S, Kanaji T (2006) IL-13: a promising therapeutic target for bronchial asthma. Curr Med Chem 13:2291–2298CrossRefPubMedGoogle Scholar
  8. 8.
    Goenka S, Kaplan MH (2011) Transcriptional regulation by STAT6. Immunol Res 50:87–96. doi: 10.1007/s12026-011-8205-2 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pulendran B, Artis D (2012) New paradigms in type 2 immunity. Science 337:431–435. doi: 10.1126/science.1221064 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Izuhara K, Ohta S, Ono J (2016) Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res 8:491–498. doi: 10.4168/aair.2016.8.6.491 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, Kadono T (2017) Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int 66:398–403. doi: 10.1016/j.alit.2016.12.002 CrossRefPubMedGoogle Scholar
  12. 12.
    Kubo M (2017) T follicular helper and TH2 cells in allergic responses. Allergol Int 66:377–381. doi: 10.1016/j.alit.2017.04.006 CrossRefPubMedGoogle Scholar
  13. 13.
    Kabata H, Moro K, Koyasu S, Asano K (2015) Group 2 innate lymphoid cells and asthma. Allergol Int 64:227–234. doi: 10.1016/j.alit.2015.03.004 CrossRefPubMedGoogle Scholar
  14. 14.
    Miyake K, Karasuyama H (2017) Emerging roles of basophils in allergic inflammation. Allergol Int 66:382–391. doi: 10.1016/j.alit.2017.04.007 CrossRefPubMedGoogle Scholar
  15. 15.
    Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118:98–104. doi: 10.1016/j.jaci.2006.02.046 CrossRefPubMedGoogle Scholar
  16. 16.
    Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, Takeuchi S, Koike K, Ono J, Noshiro H, Furue M, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 122:2590–2600. doi: 10.1172/JCI58978 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ishida A, Ohta N, Suzuki Y, Kakehata S, Okubo K, Ikeda H, Shiraishi H, Izuhara K (2012) Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 61:589–595. doi: 10.2332/allergolint.11-OA-0370 CrossRefPubMedGoogle Scholar
  18. 18.
    Stankovic KM, Goldsztein H, Reh DD, Platt MP, Metson R (2008) Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope 118:881–889. doi: 10.1097/MLG.0b013e31816b4b6f CrossRefPubMedGoogle Scholar
  19. 19.
    Fujishima H, Okada N, Matsumoto K, Fukagawa K, Igarashi A, Matsuda A, Ono J, Ohta S, Mukai H, Yoshikawa M, Izuhara K (2016) The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases. J Allergy Clin Immunol 138(459–467):e2. doi: 10.1016/j.jaci.2015.11.039 Google Scholar
  20. 20.
    Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, Stringer K, Abonia JP, Molkentin JD, Rothenberg ME (2008) Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 1:289–296. doi: 10.1038/mi.2008.15 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV (2010) Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 107:14170–14175. doi: 10.1073/pnas.1009426107 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A (2013) Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy 68:1467–1470. doi: 10.1111/all.12240 CrossRefPubMedGoogle Scholar
  23. 23.
    Sehra S, Yao W, Nguyen ET, Ahyi AN, Tuana FM, Ahlfeld SK, Snider P, Tepper RS, Petrache I, Conway SJ, Kaplan MH (2011) Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 186:4959–4966. doi: 10.4049/jimmunol.1002359 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gordon ED, Sidhu SS, Wang ZE, Woodruff PG, Yuan S, Solon MC, Conway SJ, Huang X, Locksley RM, Fahy JV (2012) A protective role for periostin and TGF-β in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 42:144–155. doi: 10.1111/j.1365-2222.2011.03840.x CrossRefPubMedGoogle Scholar
  25. 25.
    Bentley JK, Chen Q, Hong JY, Popova AP, Lei J, Moore BB, Hershenson MB (2014) Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol 134:1433–1442. doi: 10.1016/j.jaci.2014.05.029 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kanemitsu Y, Ito I, Niimi A, Izuhara K, Ohta S, Ono J, Iwata T, Matsumoto H, Mishima M (2014) Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. Am J Respir Crit Care Med 190:472–474. doi: 10.1164/rccm.201403-0562LE CrossRefPubMedGoogle Scholar
  27. 27.
    Shiraishi H, Masuoka M, Ohta S, Suzuki S, Arima K, Taniguchi K, Aoki S, Toda S, Yoshimoto T, Inagaki N, Conway SJ, Narisawa Y, Izuhara K (2012) Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int 61:563–572. doi: 10.2332/allergolint.10-OA-0297 CrossRefPubMedGoogle Scholar
  28. 28.
    Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M, Matsukura S, Kambara T, Ohta S, Izuhara K, Aihara M (2014) Periostin levels correlate disease severity and chronicity in patients with atopic dermatitis. Br J Dermatol 171:283–291. doi: 10.1111/bjd.12943 CrossRefPubMedGoogle Scholar
  29. 29.
    Taniguchi K, Arima K, Masuoka M, Ohta S, Shiraishi H, Ontsuka K, Suzuki S, Inamitsu M, Yamamoto K, Simmons O, Toda S, Conway SJ, Hamasaki Y, Izuhara K (2014) Periostin controls keratinocyte proliferation and differentiation by interacting with the paracrine IL-1α/IL-6 loop. J Invest Dermatol 134:1295–1304. doi: 10.1038/jid.2013.500 CrossRefPubMedGoogle Scholar
  30. 30.
    Noguchi T, Nakagome K, Kobayashi T, Uchida Y, Soma T, Nakamoto H, Nagata M (2016) Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol 138(1449–1452):e5. doi: 10.1016/j.jaci.2016.05.020 Google Scholar
  31. 31.
    Izuhara K, Matsumoto H, Ohta S, Ono J, Arima K, Ogawa M (2015) Recent developments regarding periostin in bronchial asthma. Allergol Int 64(Suppl):S3–S10. doi: 10.1016/j.alit.2015.04.012 CrossRefPubMedGoogle Scholar
  32. 32.
    Matsusaka M, Kabata H, Fukunaga K, Suzuki Y, Masaki K, Mochimaru T, Sakamaki F, Oyamada Y, Inoue T, Oguma T, Sayama K, Koh H, Nakamura M, Umeda A, Ono J, Ohta S, Izuhara K, Asano K, Betsuyaku T (2015) Phenotype of asthma related with high serum periostin levels. Allergol Int 64:175–180. doi: 10.1016/j.alit.2014.07.003 CrossRefPubMedGoogle Scholar
  33. 33.
    Kim MA, Izuhara K, Ohta S, Ono J, Yoon MK, Ban GY, Yoo HS, Shin YS, Ye YM, Nahm DH, Park HS (2014) Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 113:314–320. doi: 10.1016/j.anai.2014.06.014 CrossRefPubMedGoogle Scholar
  34. 34.
    Satirapoj B, Wang Y, Chamberlin MP, Dai T, LaPage J, Phillips L, Nast CC, Adler SG (2012) Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant 27:2702–2711. doi: 10.1093/ndt/gfr670 CrossRefPubMedGoogle Scholar
  35. 35.
    Satirapoj B, Witoon R, Ruangkanchanasetr P, Wantanasiri P, Charoenpitakchai M, Choovichian P (2014) Urine periostin as a biomarker of renal injury in chronic allograft nephropathy. Transplant Proc 46:135–140. doi: 10.1016/j.transproceed.2013.07.069 CrossRefPubMedGoogle Scholar
  36. 36.
    Satirapoj B, Tassanasorn S, Charoenpitakchai M, Supasyndh O (2015) Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. PLoS One 10:e0124055. doi: 10.1371/journal.pone.0124055 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, Lopez-Carrasco V, Canabal J, Villasante C, Quirce S (2015) Sputum periostin in patients with different severe asthma phenotypes. Allergy 70:540–546. doi: 10.1111/all.12580 CrossRefPubMedGoogle Scholar
  38. 38.
    Simpson JL, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Jia G, Holweg CT, Gibson PG (2016) Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med 16:67. doi: 10.1186/s12890-016-0230-4 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Inoue T, Akashi K, Watanabe M, Ikeda Y, Ashizuka S, Motoki T, Suzuki R, Sagara N, Yanagida N, Sato S, Ebisawa M, Ohta S, Ono J, Izuhara K, Katsunuma T (2016) Periostin as a biomarker for the diagnosis of pediatric asthma. Pediatr Allergy Immunol 27:521–526. doi: 10.1111/pai.12575 CrossRefPubMedGoogle Scholar
  40. 40.
    James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, Ohta S, Ek A, Middelveld R, Dahlen B, Forsberg B, Izuhara K, Dahlen SE (2017) Serum periostin relates to type-2 inflammation and lung function in asthma; data from the large population-based cohort Swedish GA(2)LEN. Allergy. doi: 10.1111/all.13181 (in press) PubMedGoogle Scholar
  41. 41.
    Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Tamari M, Hirota T, Yokoyama T, Niimi A, Mishima M (2013) Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 132:305–312. doi: 10.1016/j.jaci.2013.04.050 CrossRefPubMedGoogle Scholar
  42. 42.
    Nagasaki T, Matsumoto H, Kanemitsu Y, Izuhara K, Tohda Y, Horiguchi T, Kita H, Tomii K, Fujimura M, Yokoyama A, Nakano Y, Hozawa S, Ito I, Oguma T, Izuhara Y, Tajiri T, Iwata T, Ono J, Ohta S, Yokoyama T, Niimi A, Mishima M (2014) Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. Am J Respir Crit Care Med 190:1449–1452. doi: 10.1164/rccm.201407-1290LE CrossRefPubMedGoogle Scholar
  43. 43.
    Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, Ward JA, Ono J, Ohta S, Izuhara K, Djukanovic R, Kurukulaaratchy RJ, Chauhan A, Howarth PH (2016) Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol 138:61–75. doi: 10.1016/j.jaci.2015.11.020 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Johansson MW, Evans MD, Crisafi GM, Holweg CT, Matthews JG, Jarjour NN (2016) Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol 137:1904–1907. doi: 10.1016/j.jaci.2015.12.1346 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hoshino M, Ohtawa J, Akitsu K (2016) Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma. Respirology 21:297–303. doi: 10.1111/resp.12687 CrossRefPubMedGoogle Scholar
  46. 46.
    Kato G, Takahashi K, Izuhara K, Komiya K, Kimura S, Hayashi S (2013) Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights 8:97–105. doi: 10.4137/bmi.s12537 PubMedPubMedCentralGoogle Scholar
  47. 47.
    Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098. doi: 10.1056/NEJMoa1106469 CrossRefPubMedGoogle Scholar
  48. 48.
    Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:748–756. doi: 10.1136/thoraxjnl-2014-206719 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781–796. doi: 10.1016/s2213-2600(16)30265-x CrossRefPubMedGoogle Scholar
  50. 50.
    Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E (2015) Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3:692–701. doi: 10.1016/s2213-2600(15)00197-6 CrossRefPubMedGoogle Scholar
  51. 51.
    Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:804–811. doi: 10.1164/rccm.201208-1414OC CrossRefPubMedGoogle Scholar
  52. 52.
    Tajiri T, Matsumoto H, Gon Y, Ito R, Hashimoto S, Izuhara K, Suzukawa M, Ohta K, Ono J, Ohta S, Ito I, Oguma T, Inoue H, Iwata T, Kanemitsu Y, Nagasaki T, Niimi A, Mishima M (2016) Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy 71:1472–1479. doi: 10.1111/all.12922 CrossRefPubMedGoogle Scholar
  53. 53.
    Daines SM, Wang Y, Orlandi RR (2011) Periostin and osteopontin are overexpressed in chronically inflamed sinuses. Int Forum Allergy Rhinol 1:101–105. doi: 10.1002/alr.20031 CrossRefPubMedGoogle Scholar
  54. 54.
    Zhang W, Hubin G, Endam LM, Al-Mot S, Filali-Mouhim A, Desrosiers M (2012) Expression of the extracellular matrix gene periostin is increased in chronic rhinosinusitis and decreases following successful endoscopic sinus surgery. Int Forum Allergy Rhinol 2:471–476. doi: 10.1002/alr.21056 CrossRefPubMedGoogle Scholar
  55. 55.
    Wang M, Wang X, Zhang N, Wang H, Li Y, Fan E, Zhang L, Zhang L, Bachert C (2015) Association of periostin expression with eosinophilic inflammation in nasal polyps. J Allergy Clin Immunol 136:1700–1703. doi: 10.1016/j.jaci.2015.09.005 CrossRefPubMedGoogle Scholar
  56. 56.
    Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, Matsui S, Kudo A, Naka T, Murota H, Katayama I (2012) Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. PLoS One 7:e41994. doi: 10.1371/journal.pone.0041994 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, Aihara M, Takahashi K (2013) Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol 168:717–725. doi: 10.1111/bjd.12117 CrossRefPubMedGoogle Scholar
  58. 58.
    Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444. doi: 10.1002/1529-0131(200011)43:11<2437:aid-anr10>3.0.co;2-u CrossRefPubMedGoogle Scholar
  59. 59.
    Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, Ohshima K, Shiraishi H, Uchida M, Ono J, Ohta S, Kato S, Izuhara K, Aizawa H (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37:1119–1127. doi: 10.1183/09031936.00059810 CrossRefPubMedGoogle Scholar
  60. 60.
    Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S, Okamoto M, Ahlfeld SK, Ohshima K, Kato S, Toda S, Sagara H, Aizawa H, Hoshino T, Conway SJ, Hayashi S, Izuhara K (2012) Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 46:677–686. doi: 10.1165/rcmb.2011-0115OC CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB (2012) Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 303:L1046–L1056. doi: 10.1152/ajplung.00139.2012 CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Ashley SL, Wilke CA, Kim KK, Moore BB (2017) Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung fibrosis. Mucosal Immunol 10:341–351. doi: 10.1038/mi.2016.61 CrossRefPubMedGoogle Scholar
  63. 63.
    Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H, Kushima H, Ishii H, Akasaka K, Ono J, Kamei A, Azuma Y, Matsumoto H, Yamaguchi Y, Aihara M, Johkoh T, Kawaguchi A, Ichiki M, Sagara H, Kadota JI, Hanaoka M, Hayashi SI, Kohno S, Hoshino T, Izuhara K (2017) The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One 12:e0174547. doi: 10.1371/journal.pone.0174547 CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M, Azuma K, Kawayama T, Ohta S, Izuhara K, Hoshino T (2015) Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Investig 53:73–81. doi: 10.1016/j.resinv.2014.12.003 CrossRefPubMedGoogle Scholar
  65. 65.
    Nance T, Smith KS, Anaya V, Richardson R, Ho L, Pala M, Mostafavi S, Battle A, Feghali-Bostwick C, Rosen G, Montgomery SB (2014) Transcriptome analysis reveals differential splicing events in IPF lung tissue. PLoS One 9:e92111. doi: 10.1371/journal.pone.0092111 CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T, Fukuchi Y (2001) Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 24:264–271. doi: 10.1165/ajrcmb.24.3.4293 CrossRefPubMedGoogle Scholar
  67. 67.
    McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G (2005) Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851–7860. doi: 10.1158/1078-0432.ccr-05-0262 CrossRefPubMedGoogle Scholar
  68. 68.
    Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K (2014) Periostin in allergic inflammation. Allergol Int 63:143–151. doi: 10.2332/allergolint.13-RAI-0663 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Kenji Izuhara
    • 1
  • Satoshi Nunomura
    • 1
  • Yasuhiro Nanri
    • 1
  • Masahiro Ogawa
    • 1
  • Junya Ono
    • 1
    • 2
  • Yasutaka Mitamura
    • 1
  • Tomohito Yoshihara
    • 1
  1. 1.Division of Medical Biochemistry, Department of Biomolecular SciencesSaga Medical SchoolNabeshimaJapan
  2. 2.Shino-Test CorporationSagamiharaJapan

Personalised recommendations